Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Erythropoietin and Anemia Treatment

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the role of erythropoietin and its derivatives in the treatment and management of various diseases, including anemia, chronic kidney disease, heart failure, stroke, and cancer. It explores the use of erythropoiesis-stimulating agents, neuroprotective effects, and the impact on hypoxia-inducible factors. Additionally, it addresses the association with iron deficiency and cardiovascular disease.

318
Works

How has Erythropoietin and Anemia Treatment's publication output changed over time?

ScholarIQpublication output · 1998–2020

Output grew0% over the shown period — from 1 works in 1998 to 1 in 2020.

1
1
2
2
2
2
1
1
2
1
1998200120062008200920132014201720192020

What are the most-cited papers on Erythropoietin and Anemia Treatment?

ScholarIQmost cited works
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Francesco Locatelli, Steven Fishbane, Geoffrey A. Block, Iain C. Macdougall
American Journal of Nephrology. 20174,817 CitationsOPEN ACCESS
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Ajay Singh, Lynda A. Szczech, Kezhen L. Tang, Huiman X. Barnhart, Shelly Sapp, Marsha Wolfson, Donal Reddan
New England Journal of Medicine. 20062,763 CitationsOPEN ACCESS
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Tilman B. Drüeke, Francesco Locatelli, Naomi Clyne, Kai‐Uwe Eckardt, Iain C. Macdougall, Dimitrios Tsakiris, Hans-Ulrich Burger, Armin Scherhag
New England Journal of Medicine. 20062,104 CitationsOPEN ACCESS
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto
New England Journal of Medicine. 20092,088 CitationsOPEN ACCESS
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Stefan D. Anker, Josep Comín Colet, Gerasimos Filippatos, Ronnie Willenheimer, Kenneth Dickstein, Helmut Drexler, Thomas F. Lüscher, B. Ya. Bart, Waldemar Banasiak, Joanna Niegowska, Bridget‐Anne Kirwan, Claudio Mori, B. Rothe, Stuart Pocock, Philip A. Poole‐Wilson, Piotr Ponikowski
New England Journal of Medicine. 20092,068 CitationsOPEN ACCESS

Where is Erythropoietin and Anemia Treatment research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Erythropoietin and Anemia Treatment is open access?

ScholarIQopen access share
93%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
20%
Bronze
73%
Closed
7%

Related on ScholarIQ

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Paper
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Paper
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Paper
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Paper
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Paper
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Paper
470M+ articles · free account